

ALNYLAM PHARMACEUTICALS, INC.

Form 4

October 26, 2007

**FORM 4**

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287  
Expires: January 31, 2005  
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
Allen Patricia L

(Last) (First) (Middle)

300 THIRD STREET

(Street)

CAMBRIDGE, MA 02142

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol  
ALNYLAM  
PHARMACEUTICALS, INC.  
[ALNY]

3. Date of Earliest Transaction (Month/Day/Year)  
10/25/2007

4. If Amendment, Date Original Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

\_\_\_ Director \_\_\_ 10% Owner  
 Officer (give title below) \_\_\_ Other (specify below)

VP of Finance/Treasurer

6. Individual or Joint/Group Filing(Check Applicable Line)

Form filed by One Reporting Person  
\_\_\_ Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	(A) or (D)	5. Amount or Price	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	10/25/2007		M <sup>(1)</sup>	20,000	A	\$ 0.95	21,070	D	
Common Stock	10/25/2007		S <sup>(2)</sup>	100	D	\$ 31.54	20,970	D	
Common Stock	10/25/2007		S	100	D	\$ 31.6	20,870	D	
Common Stock	10/25/2007		S	200	D	\$ 31.61	20,670	D	
Common Stock	10/25/2007		S	100	D	\$ 31.64	20,570	D	

Edgar Filing: ALNYLAM PHARMACEUTICALS, INC. - Form 4

Common Stock	10/25/2007	S	200	D	\$ 31.67	20,370	D
Common Stock	10/25/2007	S	700	D	\$ 31.69	19,670	D
Common Stock	10/25/2007	S	1,200	D	\$ 31.7	18,470	D
Common Stock	10/25/2007	S	100	D	\$ 31.72	18,370	D
Common Stock	10/25/2007	S	100	D	\$ 31.73	18,270	D
Common Stock	10/25/2007	S	400	D	\$ 31.74	17,870	D
Common Stock	10/25/2007	S	700	D	\$ 31.78	17,170	D
Common Stock	10/25/2007	S	100	D	\$ 31.84	17,070	D
Common Stock	10/25/2007	S	100	D	\$ 31.85	16,970	D
Common Stock	10/25/2007	S	528	D	\$ 31.86	16,442	D
Common Stock	10/25/2007	S	787	D	\$ 31.87	15,655	D
Common Stock	10/25/2007	S	1,900	D	\$ 31.88	13,755	D
Common Stock	10/25/2007	S	1,900	D	\$ 31.89	11,855	D
Common Stock	10/25/2007	S	200	D	\$ 31.92	11,655	D
Common Stock	10/25/2007	S	1,800	D	\$ 31.93	9,855	D
Common Stock	10/25/2007	S	100	D	\$ 31.94	9,755	D
Common Stock	10/25/2007	S	100	D	\$ 31.96	9,655	D
Common Stock	10/25/2007	S	600	D	\$ 31.97	9,055	D
Common Stock	10/25/2007	S	300	D	\$ 31.98	8,755	D
Common Stock	10/25/2007	S	200	D	\$ 31.99	8,555	D
	10/25/2007	S	100	D		8,455	D

Edgar Filing: ALNYLAM PHARMACEUTICALS, INC. - Form 4

Common Stock					\$				32.01
Common Stock	10/25/2007		S	200	D	\$	8,255		32.02
Common Stock	10/25/2007		S	100	D	\$	8,155		32.03
Common Stock	10/25/2007		S	500	D	\$	7,655		32.04
Common Stock	10/25/2007		S	395	D	\$	7,260		32.05

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

SEC 1474  
(9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**  
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Security (Instr. 3 and 4)		
				Code	V (A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Non-Qualified Stock Option (right to buy)	\$ 0.95	10/25/2007		M <sup>(1)</sup>	20,000	05/17/2005	05/04/2014	Common Stock	20,000

## Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Allen Patricia L 300 THIRD STREET CAMBRIDGE, MA 02142			VP of Finance/Treasurer	

## Signatures

/s/ Patricia L.  
Allen

10/26/2007

\_\_Signature of  
Reporting Person

Date

## Explanation of Responses:

- \* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
  - \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) This exercise is pursuant to a 10b5-1 plan put in place by the reporting person on September 25, 2007.
  - (2) All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 25, 2007.

### Remarks:

This Form 4 is the first of two filed by the reporting person to report transactions occurring on October 25, 2007.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.